不同炎症小体激活模式 predispose 代偿与再代偿肝硬化患者发生慢加急性肝衰竭
研究前瞻性随访249例肝硬化患者(代偿与再代偿),并在两个外部队列(n=327)验证,发现再代偿患者及可检测到ILs的患者ACLF发生率更高;代偿患者中基线CLIF-C AD、白蛋白和IL-1α为ACLF独立预测因子,再代偿患者中CLIF-C AD和IL-1β为独立预测因子。大鼠模型证实代偿期肝硬化与IL-1α相关、再代偿期肝硬化与IL-1β相关。
要点
- 再代偿(既往AD)是致命性ACLF的重要危险因素。
- 代偿肝硬化ACLF预测因子包括CLIF-C AD、白蛋白和IL-1α。
- 再代偿肝硬化ACLF预测因子包括CLIF-C AD和IL-1β。
核心结论
- 既往AD是致命性ACLF发展的重要危险因素,并可能与炎症小体激活相关。
- 动物模型证实代偿期肝硬化ACLF发展与IL-1α相关,再代偿期肝硬化与IL-1β相关。
研究设计与样本
- 前瞻性随访249例肝硬化患者,分为代偿组和再代偿组(既往AD),观察致命性ACLF发展。
- 纳入两个外部队列(n=327)进行验证,包括再代偿、AD和ACLF患者。
- 检测炎症小体驱动白介素IL-1α(caspase-4/11依赖)和IL-1β(caspase-1依赖)。
- 大鼠采用胆管结扎诱导肝硬化及脂多糖暴露诱导AD和后续再代偿,检测IL-1α、IL-1β水平及上下游基因表达。
主要发现
- 发生ACLF的患者基线ILs水平更高。
- 再代偿患者和可检测到ILs的患者ACLF发生率高于代偿患者。
- 代偿患者中基线CLIF-C AD、白蛋白和IL-1α是ACLF发展的独立预测因子。
- 再代偿患者中CLIF-C AD和IL-1β是ACLF发展的独立预测因子。
- 代偿大鼠IL-1α基因表达更高,再代偿大鼠IL-1β水平及肝脏基因表达更高。
临床怎么用
- 对再代偿(既往AD)肝硬化患者应警惕致命性ACLF风险。
- 代偿肝硬化可检测基线IL-1α、白蛋白和CLIF-C AD以评估ACLF风险。
- 再代偿肝硬化可检测基线IL-1β和CLIF-C AD以评估ACLF风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic inflammation predisposes acutely decompensated (AD) cirrhosis to the development of acute-on-chronic liver failure (ACLF). Supportive treatment can improve AD patients, becoming recompensated. Little is known about the outcome of patients recompensated after AD. We hypothesise that different inflammasome activation is involved in ACLF development in compensated and recompensated patients. DESIGN: 249 patients with cirrhosis, divided into compensated and recompensated (previous AD), were followed prospectively for fatal ACLF development. Two external cohorts (n=327) (recompensation, AD and ACLF) were included. Inflammasome-driving interleukins (ILs), IL-1α (caspase-4/11-dependent) and IL-1β (caspase-1-dependent), were measured. In rats, bile duct ligation-induced cirrhosis and lipopolysaccharide exposition were used to induce AD and subsequent recompensation. IL-1α and IL-1β levels and upstream/downstream gene expression were measured. RESULTS: Patients developing ACLF showed higher baseline levels of ILs. Recompensated patients and patients with detectable ILs had higher rates of ACLF development than compensated patients. Baseline CLIF-C (European Foundation for the study of chronic liver failure consortium) AD, albumin and IL-1α were independent predictors of ACLF development in compensated and CLIF-C AD and IL-1β in recompensated patients. Compensated rats showed higher IL-1α gene expression and recompensated rats higher IL-1β levels with higher hepatic gene expression. Higher IL-1β detection rates in recompensated patients developing ACLF and higher IL-1α and IL-1β detection rates in patients with ACLF were confirmed in the two external cohorts. CONCLUSION: Previous AD is an important risk factor for fatal ACLF development and possibly linked with inflammasome activation. Animal models confirmed the results showing a link between ACLF development and IL-1α in compensated cirrhosis and IL-1β in recompensated cirrhosis.
引用
- Monteiro S, Grandt J, Uschner FE, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut. 2020. PMID: 32241903. doi:10.1136/gutjnl-2019-320170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。